These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37852124)

  • 1. Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Alqahtani A; Alloghbi A; Coffin P; Yin C; Mukherji R; Weinberg BA
    Surg Oncol; 2023 Dec; 51():102007. PubMed ID: 37852124
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Implications of Pre- and Postoperative Circulating Tumor DNA in Patients with Resected Pancreatic Ductal Adenocarcinoma.
    Yamaguchi T; Uemura K; Murakami Y; Kondo N; Nakagawa N; Okada K; Seo S; Hiyama E; Takahashi S; Sueda T
    Ann Surg Oncol; 2021 Jun; 28(6):3135-3144. PubMed ID: 33128119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.
    Watanabe F; Suzuki K; Tamaki S; Abe I; Endo Y; Takayama Y; Ishikawa H; Kakizawa N; Saito M; Futsuhara K; Noda H; Konishi F; Rikiyama T
    PLoS One; 2019; 14(12):e0227366. PubMed ID: 31891652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer.
    Groot VP; Mosier S; Javed AA; Teinor JA; Gemenetzis G; Ding D; Haley LM; Yu J; Burkhart RA; Hasanain A; Debeljak M; Kamiyama H; Narang A; Laheru DA; Zheng L; Lin MT; Gocke CD; Fishman EK; Hruban RH; Goggins MG; Molenaar IQ; Cameron JL; Weiss MJ; Velculescu VE; He J; Wolfgang CL; Eshleman JR
    Clin Cancer Res; 2019 Aug; 25(16):4973-4984. PubMed ID: 31142500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic impact of postoperative circulating tumor DNA as a molecular minimal residual disease marker in patients with pancreatic cancer undergoing surgical resection.
    Hata T; Mizuma M; Motoi F; Ohtsuka H; Nakagawa K; Morikawa T; Unno M
    J Hepatobiliary Pancreat Sci; 2023 Jun; 30(6):815-824. PubMed ID: 36408698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.
    Bernard V; Kim DU; San Lucas FA; Castillo J; Allenson K; Mulu FC; Stephens BM; Huang J; Semaan A; Guerrero PA; Kamyabi N; Zhao J; Hurd MW; Koay EJ; Taniguchi CM; Herman JM; Javle M; Wolff R; Katz M; Varadhachary G; Maitra A; Alvarez HA
    Gastroenterology; 2019 Jan; 156(1):108-118.e4. PubMed ID: 30240661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
    Lee B; Lipton L; Cohen J; Tie J; Javed AA; Li L; Goldstein D; Burge M; Cooray P; Nagrial A; Tebbutt NC; Thomson B; Nikfarjam M; Harris M; Haydon A; Lawrence B; Tai DWM; Simons K; Lennon AM; Wolfgang CL; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P
    Ann Oncol; 2019 Sep; 30(9):1472-1478. PubMed ID: 31250894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.
    Lee JS; Rhee TM; Pietrasz D; Bachet JB; Laurent-Puig P; Kong SY; Takai E; Yachida S; Shibata T; Lee JW; Park HC; Zang DY; Jeon K; Lee J; Kim M; Kim HS; Kang HJ; Lee YK
    Sci Rep; 2019 Nov; 9(1):16971. PubMed ID: 31740696
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis.
    Bunduc S; Gede N; Váncsa S; Lillik V; Kiss S; Dembrovszky F; Eróss B; Szakács Z; Gheorghe C; Mikó A; Hegyi P
    Crit Rev Oncol Hematol; 2022 Jan; 169():103548. PubMed ID: 34843928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an Independent Predictor of Clinical Outcome.
    Shoucair S; Habib JR; Pu N; Kinny-Köster B; van Ooston AF; Javed AA; Lafaro KJ; He J; Wolfgang CL; Yu J
    Ann Surg Oncol; 2022 Apr; 29(4):2720-2731. PubMed ID: 34792696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of personalized and tumor-informed ctDNA with patient survival outcomes in pancreatic adenocarcinoma.
    Botta GP; Abdelrahim M; Drengler RL; Aushev VN; Esmail A; Laliotis G; Brewer CM; George GV; Abbate SM; Chandana SR; Tejani MA; Malla M; Bansal D; Rivero-Hinojosa S; Spickard E; McCormick N; Cecchini M; Lacy J; Fei N; Kasi PM; Kasi A; Dayyani F; Hanna DL; Sharma S; Malhotra M; Aleshin A; Liu MC; Jurdi A
    Oncologist; 2024 Oct; 29(10):859-869. PubMed ID: 39022993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma.
    Nitschke C; Markmann B; Walter P; Badbaran A; Tölle M; Kropidlowski J; Belloum Y; Goetz MR; Bardenhagen J; Stern L; Tintelnot J; Schönlein M; Sinn M; van der Leest P; Simon R; Heumann A; Izbicki JR; Pantel K; Wikman H; Uzunoglu FG
    Clin Chem; 2023 Mar; 69(3):295-307. PubMed ID: 36644936
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preoperative detection of KRAS mutated circulating tumor DNA is an independent risk factor for recurrence in colorectal cancer.
    Nakamura Y; Yokoyama S; Matsuda K; Tamura K; Mitani Y; Iwamoto H; Mizumoto Y; Murakami D; Kitahata Y; Yamaue H
    Sci Rep; 2021 Jan; 11(1):441. PubMed ID: 33432066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of absolute quantification of mutated KRAS in circulating tumour DNA in lung adenocarcinoma patients prior to therapy.
    Wahl SGF; Dai HY; Emdal EF; Ottestad AL; Dale VG; Richardsen E; Halvorsen TO; Grønberg BH
    J Pathol Clin Res; 2021 May; 7(3):209-219. PubMed ID: 33502820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.
    Patel H; Okamura R; Fanta P; Patel C; Lanman RB; Raymond VM; Kato S; Kurzrock R
    J Hematol Oncol; 2019 Dec; 12(1):130. PubMed ID: 31801585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. KRAS mutations in cell-free DNA from preoperative and postoperative sera as a pancreatic cancer marker: a retrospective study.
    Nakano Y; Kitago M; Matsuda S; Nakamura Y; Fujita Y; Imai S; Shinoda M; Yagi H; Abe Y; Hibi T; Fujii-Nishimura Y; Takeuchi A; Endo Y; Itano O; Kitagawa Y
    Br J Cancer; 2018 Mar; 118(5):662-669. PubMed ID: 29360815
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal analysis of cell-free mutated KRAS and CA 19-9 predicts survival following curative resection of pancreatic cancer.
    Hussung S; Akhoundova D; Hipp J; Follo M; Klar RFU; Philipp U; Scherer F; von Bubnoff N; Duyster J; Boerries M; Wittel U; Fritsch RM
    BMC Cancer; 2021 Jan; 21(1):49. PubMed ID: 33430810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of preoperative circulating tumor DNA in non-small cell lung cancer: a systematic review and meta-analysis.
    Lu J; Feng Y; Guo K; Sun L; Ruan S; Zhang K
    J Cancer Res Clin Oncol; 2024 Jan; 150(1):25. PubMed ID: 38252173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.
    Guo S; Shi X; Shen J; Gao S; Wang H; Shen S; Pan Y; Li B; Xu X; Shao Z; Jin G
    Br J Cancer; 2020 Mar; 122(6):857-867. PubMed ID: 31969677
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.